About KPC Pharmaceuticals, Inc.
KPC Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Kunming, Yunnan, founded in March 1951 as Kunming Pharmaceutical Corporation and listed on the Shanghai Stock Exchange since December 2000 (600422). According to its official English website, it ranks among the top 100 companies in the Chinese medical industry and operates a large pharmaceutical science and technology park in the National Biological Industry Base of the Kunming High-tech Zone.
Its speciality is innovative natural botanical drugs developed from Yunnan's plant resources. Highlights include the artemether series against malaria — its artemether injection is on the WHO Model List of Essential Medicines — the Panax notoginseng (sanchi) series for cardiovascular and cerebrovascular diseases, and the gastrodine series for nervous system disorders, under brands such as Luotai, Tianxuanqing, Artemedine, Artem and Arco, with more than forty patented new botanical drugs.
The group integrates R&D, production, marketing, commercial wholesale and international marketing, and includes subsidiaries such as Kunming Traditional Chinese Medicine, Xishuangbanna Pharmaceutical and Beijing Holley-Cotec. Its motto, 'From nature; for human health', sums up a strategy focused on cardiovascular and chronic disease treatments with global ambitions.
Its speciality is innovative natural botanical drugs developed from Yunnan's plant resources. Highlights include the artemether series against malaria — its artemether injection is on the WHO Model List of Essential Medicines — the Panax notoginseng (sanchi) series for cardiovascular and cerebrovascular diseases, and the gastrodine series for nervous system disorders, under brands such as Luotai, Tianxuanqing, Artemedine, Artem and Arco, with more than forty patented new botanical drugs.
The group integrates R&D, production, marketing, commercial wholesale and international marketing, and includes subsidiaries such as Kunming Traditional Chinese Medicine, Xishuangbanna Pharmaceutical and Beijing Holley-Cotec. Its motto, 'From nature; for human health', sums up a strategy focused on cardiovascular and chronic disease treatments with global ambitions.